(2019). Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis. test, 3(1), -. doi: 10.21608/cvrepj.2019.351824
. "Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis". test, 3, 1, 2019, -. doi: 10.21608/cvrepj.2019.351824
(2019). 'Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis', test, 3(1), pp. -. doi: 10.21608/cvrepj.2019.351824
Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis. test, 2019; 3(1): -. doi: 10.21608/cvrepj.2019.351824

Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis

Cardiovascular Research Prove Journal
Volume 3, Issue 1, June 2019    PDF (34.72 K)
Document Type: Abstracts
DOI: 10.21608/cvrepj.2019.351824
Abstract
Pristimerin (Pris) is triterpenoid compound with many 
biological effects. Until now, nothing is known about 
its effect on doxorubicin (DOX)-induced 
cardiotoxicity. Hence, this study investigated the 
impact of Pris on DOX-induced cardiotoxic effects. 
Statistics
Article View: 31
PDF Download: 18